Related Experiment Video
Updated: Jan 18, 2026
07:32
Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model
Published on: December 28, 2021
4.4K
Recent advances in treating Parkinson's disease.
1Department of Neurology, University Clinic, Philipps Universität Marburg, Marburg, Germany; Institute for Neurogenomics, Helmholtz Center for Health and Environment, Munich, Germany.
F1000Research
|March 31, 2017
Summary
This review covers advances in Parkinson
Area of Science:
- Neurology and Neuroscience
- Pharmacology and Therapeutics
Background:
- Parkinson's disease (PD) management focuses on symptomatic relief for motor and non-motor symptoms.
- Developing disease-modifying treatments for existing Parkinson's disease is an active area of research.
- Preventing Parkinson's disease in its early stages remains a significant challenge.
Purpose of the Study:
- To summarize recent progress in symptomatic therapies for Parkinson's disease (PD).
- To highlight efforts in treating non-motor symptoms of PD.
- To review advancements in disease-modifying treatments for manifest PD and discuss challenges in prodromal PD prevention.
Main Methods:
- Review of recent scientific literature on Parkinson's disease therapeutics.
- Analysis of clinical trial developments for symptomatic and disease-modifying treatments.
- Discussion of methodological challenges in prodromal PD research, including endpoint selection.
Main Results:
- Significant achievements have been made in improving symptomatic therapies for motor symptoms of Parkinson's disease.
- Limited progress has been observed in systematically developing symptomatic therapies for non-motor symptoms.
- Advances in compounds for disease modification in manifest PD are promising, but prevention remains elusive.
Conclusions:
- Current research shows progress in managing Parkinson's disease symptoms and developing disease-modifying treatments.
- A lack of consensus on primary endpoints for prodromal Parkinson's disease trials hinders prevention research.
- Future efforts must address methodological challenges to enable effective prevention strategies for Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
01:28Drug Therapy
246
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
246
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:21EPS and iPS Cells in Disease Research
3.4K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.4K